

## **A new Patient-Centered Endowment Fund launches by France Biotech: “HealthTech For Care”**

- **More than ever, access of all patients to medical innovation is a major economic and societal challenge.**
- **The fund will actively contribute to building a stronger and sovereign healthcare ecosystem in France and Europe to accelerate access to innovative healthcare solutions for all patients.**

**Paris, April 2, 2020** – A new patient-centered endowment fund, HealthTech For Care, has been launched by France Biotech to accelerate patient access to healthcare solutions, and to contribute to building a stronger healthcare ecosystem in France and Europe from academic research to entrepreneurship, manufacturing and commercialization of innovative medical solutions. Healthtech For Care’s approach involves the open-up of all the ecosystem involved in HealthTech innovation, from research departments, companies developing new technologies, pharmaceutical companies, and public and private investors. To this end, the Fund wishes to increase exchanges between these players with a view to bringing therapeutic solutions under development to market more quickly for the benefit of all patients.

HealthTech For Care has three main goals:

- Facilitate a stronger understanding and coordination between health professionals’ practice areas, in order to further medical research and benefit patients ;
- Promote exchanges and dissemination of information on innovative therapies, treatments and therapeutic approaches through dedicated, patient-focused conferences and events with patient’s association ;
- Provide all patients with more efficient care in the shortest possible time.

Founded by France Biotech, Maryvonne Hiance, VP and co-founder of OSE Immunotherapeutics, and several key players of the industry, HealthTech For Care will foster access to innovative healthcare solutions for all patients through the organization of Europe-focused initiatives and events. These events will bring together the players involved in the medical innovation value chain, such as academic researchers, entrepreneurs, manufacturers and leaders in the commercialization of new medical technologies and new drugs.

HealthTech For Care’s first event will be the HealthTech Innovation Days (HTID®), that will be held in Paris on October 5 & 6, 2020. This event, which was launched in 2019 by France Biotech, brings together leaders in HealthTech, international pharma, patient associations and public and private investors to advance and accelerate development of healthcare solutions. The HTID® will support the development of European HealthTech companies through thematic roundtables on new life sciences trends, networking opportunities and private meetings between entrepreneurs, international pharma companies, global

healthcare investors, KOLs and other experts in the field. For more information, visit the event website: <http://www.htid-paris.com/>

*"More than ever, we are aware that access to medical innovation for all patients is a major economic and societal challenge. We have therefore created HealthTech For Care, with an approach that puts the interests of patients at the heart of our concerns. We are convinced that the quality of interactions between the various players is a determining factor in accelerating the transition from research to market and enabling faster access for all patients to new medical solutions. The Endowment Fund will push the goals of the HTID® forward by funding an event that contributes directly to the sustainable future of healthcare, and to advancing access to cutting-edge technologies in HealthTech for all patients."* said Maryvonne Hiance, President of HealthTech For Care.

*"France Biotech has designed the HealthTech For Care instrument to boost its ability to federate, structure and encourage cooperation between the various stakeholders in the HealthTech sector in France and Europe. The various actions carried out with the help of this endowment fund are ultimately aimed at ensuring that the innovative solutions we develop benefit patients as quickly as possible."* continues Franck Mouthon, President of France Biotech.

#### **About HealthTech For Care**

The HealthTech For Care endowment fund is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. The missions of the endowment fund are structured around three main areas: Supporting the development of the entire health ecosystem, accelerating the development of innovative therapies and treatments, and promoting better access to healthcare for patients in the French healthcare system and more widely throughout Europe. HealthTech For Care is administrated by Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.

#### **About HTID®**

The purpose of the event is to drive and foster collaborations within the European healthcare and life sciences ecosystems. The HealthTech Innovation Days bring the European healthcare community together to discuss new trends in research & development. This symposium also features conferences and panel discussions, networking and private meetings between innovative European HealthTech companies, pharmaceutical companies, life sciences-specialized investors, healthcare experts, KOLs and institutional representatives. In addition to the ongoing private networking, attendees can expect roundtables focused on critical economic and political issues that impact health technology developments. The HealthTech Innovation Days are intended for publicly listed companies whose market capitalization is at least €20 million, or for privately held Biotech firms whose drug candidates are currently undergoing late Phase I studies. For MedTech companies, medical devices must have already obtained the CE mark in Europe or FDA approval in the United States. Details of the roundtables will be announced in the coming weeks. HTID® 2020 will be held on October 5&6 in Paris. <http://www.htid-paris.com/>

#### **About France Biotech**

Founded in 1997, France Biotech is an independent association that brings together HealthTech entrepreneurs and their expert partners. It actively contributes to meet the many challenges of the HealthTech industry (i.e. companies' financing, innovation-related taxes, regulatory and market access related issues) and offers concrete competition and solutions through its commissions and working groups. The goal is to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. <http://www.france-biotech.fr>

## Press Contacts

### HTID®

Nathalie Donne

[Nathalie.donne@shapenlink.com](mailto:Nathalie.donne@shapenlink.com)

+33(0)6 67 67 44 97

### RooneyPartners LLC – NORTH AMERICA

Kate Barrette

[kbarrette@rooneyco.com](mailto:kbarrette@rooneyco.com)

+1.212.223.0561

### StrategiesImage (S&I) – FRANCE

Anne Rein

[anne.rein@strategiesimage.com](mailto:anne.rein@strategiesimage.com)

+33(0)6 03 35 92 05

### MC Services AG – GERMANY

Anne Hennecke

[Anne.hennecke@mc-services.eu](mailto:Anne.hennecke@mc-services.eu)

+49 211 529 252 22



**MC SERVICES**